Mankind Pharma Q2 Results 2025 Highlights: Net Profit Falls 21.72% & Revenue Up 20.77% YoY

Click and Sign Up to Get Live Updates on Q2 Results 

Mankind Pharma Q2 Results FY26: During Q2 FY26, Mankind Pharma’s profit decreased 21.72% YoY, while revenue increased by 20.77% YoY. The company posted robust numbers, with Q2 PAT at ₹511.51 crores and revenue at ₹3,697.16 crores. Mankind Pharma announced its Q2 results on 6th November 2025.  

Mankind Pharma Q2 Results FY26: Extracts of FY25 & FY26 (Consolidated Figures)

(Figures in crores)

Mankind Pharma Q2 Results FY26: Extracts of FY25 & FY26 (Standalone Figures)

(Figures in crores)

Mankind Pharma Q2 Results FY26 Highlights (Q2 FY26 vs FY25)

• Mankind Pharma clocked Q2 FY26 consolidated revenue of ₹3,697.16 crores vs ₹3,061.43 crores. 
• On the profit front, Mankind Pharma earned a consolidated PAT of ₹511.51 crore in Q2 FY26. During FY25, the company’s PAT stood at ₹653.47 crore.
• According to the consolidated figures, Mankind Pharma’s quarterly PAT decreased by 21.75% YoY, while revenue increased by 20.77%.
• Mankind Pharma clocked Q2 FY26 standalone revenue of ₹2,608.78 crores vs ₹2,544.18 crores. 
• On the profit front, Mankind Pharma earned a standalone PAT of ₹458.90 crore in Q2 FY26. During FY25, the company’s PAT stood at ₹613.35 crore.
• According to the standalone figures, Mankind Pharma’s quarterly PAT decreased by 25.18% YoY, while revenue increased by 2.54%.

Download the Univest iOS App or Univest Android App to get daily stock recommendations and insightful research pieces!

Mankind Pharma Share Price Performance

On the opening bell on 10th November 2025, Mankind Pharma shares opened at ₹2,271.80 per share. However, the initial gains have since eroded, and Mankind Pharma shares are currently trading at ₹2,240.00 per share, which is lower than the opening price.    

Considering the long-term achievements, Mankind Pharma shares have yielded returns of approximately -10.48% over the past 6 months, and 1-year returns stand at -15.44%. Over the maximum timeframe, Mankind Pharma shares delivered a 60.49% return to investors. 

What Analysts Expect Post Q2 Results?

Following Mankind Pharma’s robust Q2 results, analysts expect its share price to rise. According to analysts, Mankind Pharma’s share price is expected to reach ₹2,380.20 per share in the coming year; however, in a downturn, it could fall to ₹2,200.60 per share. However, one must ignore stock market volatility and invest in Mankind Pharma’s shares after thorough research. 

Disclaimer: Investment in the share market is subject to risk. This news article is for informational purposes only. Conduct your own research before investing in shares and other securities.

Recent Articles

Nestle Q2 Results FY26: Q2 PAT Falls 17.38% to ₹743.17 Crore; Revenue Up 10.57% YoY

Inspira Enterprise India IPO Details: Everything You Should Know about 

Swaraj Engines Q2 Results FY26: Q2 PAT Rises 8.88% to ₹49 Crore; Revenue Up 8.62% YoY

HDB Financial Q2 Results FY26: Q2 PAT Falls 1.5% to ₹581 Crore; Revenue Up 13.42% YoY

BEL Gears Up for Q2 Reveal on 4th November; Check Key Expectations Here

Paytm Gears Up for Q2 Reveal on 4th November; Check Key Expectations Here

Blue Dart Gears Up for Q2 Reveal on 28th October; Check Key Expectations Here